Lumicell

06/16/2026

Despite advances in imaging and pathology, residual disease can still go undetected during lumpectomy.

In diffuse or nonpalpable DCIS, what remains may never be visible with traditional approaches.

What if you could visualize suspected residual disease - in real time?

Learn about the intraoperative technology that helps surgeons identify what may otherwise be left behind in the breast cavity at https://lumisystem.com/

06/09/2026

With LumiSystem, surgeons gain something powerful at the moment it matters most—confidence at the close.

By providing real-time, intraoperative insight directly within the cavity, LumiSystem helps guide more informed surgical closures for every patient.

06/04/2026

Proud to see Lumicell featured by —sharing lessons from our journey bringing fluorescence-guided surgery to market.

Key Lessons:
✔️ Align early with FDA
✔️ Design around the indication
✔️ Plan for drug-device complexity and coordinated reimbursement

A great perspective on the complexity of drug-device innovation and what it takes to translate technology into real-world clinical impact.

👉 Read the full blog:

Discover Lumicell's innovative approach to fluorescence-guided surgery, addressing key challenges in intraoperative margin assessment for breast cancer.

06/01/2026

Adjuvant therapy and post surgical treatments are critical in the fight against cancer—but surgery remains the foundation.

What happens in the OR can shape everything that follows.

That’s why real time intraoperative insight matters. By providing actionable information at the point of care, LumiSystem helps surgeons identify and remove residual cancer when it matters most—during the initial procedure.

In the Pivotal study, LumiSystem helped guide the removal of residual tumors, including sizeable disease up to 13 mm, contributing to improved surgical outcomes for 1 in 10 patients*.

Learn more at https://lumisystem.com/

* Smith et al., NEJM Evidence 2, no. 7 (June 27, 2023)

05/28/2026

We're thrilled to announce the promotion of Marnie Curbow to Chief Commercial Officer at Lumicell!🎉

Since joining in October 2025 as Vice President of Sales, Marnie has built our commercial organization from the ground up: leading sales, marketing, reimbursement, and now clinical applications. Her leadership has been instrumental in shaping our go-to-market strategy as we advance our fluorescence-guided breast surgery platform.

Congratulations, Marnie — you earned this. Thank you for bringing the light to our customers and team every day!

05/25/2026

This Memorial Day, we honor and remember those who gave their lives in service to our country.

At Lumicell, we’re grateful for their courage and sacrifice—and for the freedoms they protect. Their service inspires us every day as we work to improve the lives of patients and those who care for them.

Wishing you a meaningful and reflective Memorial Day.

05/18/2026

DCIS can extend beyond what imaging and specimen-based tools can reveal, making margin assessment especially challenging. Residual disease may remain because traditional intraoperative methods can’t directly visualize what remains in the breast cavity.

LumiSystem® is the first and only technology designed to illuminate suspected residual cancer in the breast cavity in real-time, giving surgeons added insight to address risk of positive margins and re-excision.

Learn more https://lumisystem.com/

05/11/2026

Confidence matters when moving forward with oncoplastic technique. Real-time visualization of suspected residual cancer can help surgeons navigate some of the challenges in oncoplastic breast-conserving surgery.

LumiSystem® illuminates suspected residual cancer in the breast cavity to help support more informed surgical decisions when it matters most.

Learn more https://lumisystem.com/

04/28/2026

ASBrS 2026 is nearly here and we can’t wait to connect in Seattle! ✈️🏙️🤝

🩺 ASBrS 2026
📅 April 29-May 3

Don’t forget…there are plenty of ways to engage with us while there!

-Visit us at Booth 423 to see the technology live and race your colleagues to .

-Meet our Leadership team at our booth or over a relaxed evening dinner event.

-Bonus for Breast Fellows – We’ll be at The Fellows Workshop on Thursday April 30 with hands-on demonstrations of our technology.

See you in Seattle!

04/22/2026

Now live 🎥

We’re proud to share Lumicell’s feature on Health Uncensored with Dr. Drew!

The segment focuses on the challenges surgeons face in identifying residual cancer during lumpectomy procedures and the potential impact of enhanced intraoperative visualization.

Watch here: https://www.youtube.com/watch?v=86LUsJhMhJE

Important Safety Information:
The most common side effects with LUMISIGHT(TM) (pegulicianine) are hypersensitivity and an abnormal color in urine. LUMISIGHT may cause serious hypersensitivity reactions, including anaphylaxis. Please see the LUMISIGHT Prescribing Information (https://lumisystem.com/prescribing-information/), including Boxed Warning, and Lumicell DVS Instructions for Use (https://lumisystem.com/instructions-for-use/) . For complete product information, visit www.LumiSystem.com.

1 like. "Changing the Face of Surgical Oncology"